What is the potential of statins in the treatment of depression?

Click to increase image sizeClick to decrease image size

Declaration of Interest

N De Uribe Viloria is employed by Hospital Clínico Universitario in Valladolid, Spain, and is currently collaborating as a visiting researcher with the Institute for Mental and Physical Health and Clinical Translation, Barwon Health, Geelong, Australia. M Berk is employed by the Institute for Mental and Physical Health and Clinical Translation and Barwon Health, Geelong, Australia. He has received grant/research support from Stanley Medical Research Foundation, NIH, MBF, NHMRC, NHMRC Senior Principal Research Fellowship (1059660 and 1156072), Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, MBF, Rotary Health, Meat and Livestock Board, Woolworths, BeyondBlue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, and Servier. He has also received speaker fees from Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Lundbeck, Pfizer, Sanofi Synthelabo, Servier, Solvay, and Wyeth. He has received consultancy funding from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Bioadvantex, Merck, Glaxo SmithKline, Lundbeck, Janssen Cilag, and Servier. Finally, M Berk is a co-inventor of two provisional patents regarding the use of NAC and related compounds for psychiatric indications, which, while assigned to the Mental Health Research Institute, could lead to personal remuneration upon a commercialization event. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.